Literature DB >> 2153156

Benzodiazepine binding sites in amygdala and hippocampus of depressed suicide victims.

G M Stocks1, S C Cheetham, M R Crompton, C L Katona, R W Horton.   

Abstract

Benzodiazepine binding was measured in amygdala and hippocampus from 19 suicides in whom a firm diagnosis of depression was established retrospectively, and 19 well-matched controls. The number and affinity of benzodiazepine binding sites did not differ significantly between the drug-free or drug-treated suicides and controls.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2153156     DOI: 10.1016/0165-0327(90)90112-l

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  4 in total

1.  Normal [3H]flunitrazepam binding to GABAA receptors in the locus coeruleus in major depression and suicide.

Authors:  He Zhu; Beata Karolewicz; Emily Nail; Craig A Stockmeier; Katalin Szebeni; Gregory A Ordway
Journal:  Brain Res       Date:  2006-11-21       Impact factor: 3.252

2.  Chronic administration of the antidepressants phenelzine, desipramine, clomipramine, or maprotiline decreases binding to 5-hydroxytryptamine2A receptors without affecting benzodiazepine binding sites in rat brain.

Authors:  K G Todd; D J McManus; G B Baker
Journal:  Cell Mol Neurobiol       Date:  1995-06       Impact factor: 5.046

3.  Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results.

Authors:  Ursula M H Klumpers; Dick J Veltman; Madeleine L Drent; Ronald Boellaard; Emile F I Comans; Gerben Meynen; Adriaan A Lammertsma; Witte J G Hoogendijk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-05       Impact factor: 9.236

Review 4.  Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants.

Authors:  Alan L Pehrson; Connie Sanchez
Journal:  Drug Des Devel Ther       Date:  2015-01-19       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.